<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/79012870-9471-4652-B076-44ACDCF6911E"><gtr:id>79012870-9471-4652-B076-44ACDCF6911E</gtr:id><gtr:name>Biotie Therapies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76CD45AC-378E-4073-94E5-C7DFBA3B4719"><gtr:id>76CD45AC-378E-4073-94E5-C7DFBA3B4719</gtr:id><gtr:name>University of Turku</gtr:name><gtr:address><gtr:line1>Turun yliopisto</gtr:line1><gtr:postCode>FI-20014</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2FA3213C-7C67-47E7-9961-9C57925D399A"><gtr:id>2FA3213C-7C67-47E7-9961-9C57925D399A</gtr:id><gtr:name>Perspectum Diagnosis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D9EF222D-133C-42B9-AE9E-0CD8F807C5FF"><gtr:id>D9EF222D-133C-42B9-AE9E-0CD8F807C5FF</gtr:id><gtr:name>Proximagen</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/79012870-9471-4652-B076-44ACDCF6911E"><gtr:id>79012870-9471-4652-B076-44ACDCF6911E</gtr:id><gtr:name>Biotie Therapies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76CD45AC-378E-4073-94E5-C7DFBA3B4719"><gtr:id>76CD45AC-378E-4073-94E5-C7DFBA3B4719</gtr:id><gtr:name>University of Turku</gtr:name><gtr:address><gtr:line1>Turun yliopisto</gtr:line1><gtr:postCode>FI-20014</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2FA3213C-7C67-47E7-9961-9C57925D399A"><gtr:id>2FA3213C-7C67-47E7-9961-9C57925D399A</gtr:id><gtr:name>Perspectum Diagnosis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D9EF222D-133C-42B9-AE9E-0CD8F807C5FF"><gtr:id>D9EF222D-133C-42B9-AE9E-0CD8F807C5FF</gtr:id><gtr:name>Proximagen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/464D389D-37E8-4F35-8E73-3DE6F1D2DA17"><gtr:id>464D389D-37E8-4F35-8E73-3DE6F1D2DA17</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Harvey</gtr:otherNames><gtr:surname>Adams</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2B0F97E4-31D8-4D0A-9F3D-BCBF30B574C5"><gtr:id>2B0F97E4-31D8-4D0A-9F3D-BCBF30B574C5</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Wakelam</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300101"><gtr:id>BBE5ED00-FA1A-4D7A-857A-866C1A1A6A98</gtr:id><gtr:title>Lymphocyte ligands for the endothelial adhesion molecule vascular adhesion protein-1</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300101</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>253446</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:description>Edinburgh</gtr:description><gtr:id>4A4278E2-7A65-4766-861A-E597D974414C</gtr:id><gtr:impact>Ongoing publications and research collaborations</gtr:impact><gtr:outcomeId>5A2D118C5EC-1</gtr:outcomeId><gtr:partnerContribution>We have several ongoing collaborations sharing technology and expertise</gtr:partnerContribution><gtr:piContribution>We have developed a successful local collaboration with my colleague Dr Newsome andPorfs Forbes and Iredale in Edinburgh resulting an ongoing collaboration which ahs contributed to a recent MRC grant awarded in 2009.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Proximagen</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Proximagen</gtr:description><gtr:id>6FBB214A-8844-4C04-A583-B38D5A06E3A2</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>oJo1aMCeiLH-1</gtr:outcomeId><gtr:partnerContribution>Proximagen produce a VAP-1 antagonist</gtr:partnerContribution><gtr:piContribution>Looking at SSAO inhibitors in leukocyte trafficking</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical trial of anti-VAP-1</gtr:description><gtr:id>3CCD0BC1-5F10-4FED-9AB4-B655B3C4A706</gtr:id><gtr:impact>Award of grant EME 
Project:12/165/31 - Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC).</gtr:impact><gtr:outcomeId>5452529b9e4c86.98116214-1</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients and trial design</gtr:partnerContribution><gtr:piContribution>Led successful EME application to fund a clinical trial involving Oxford hepatologists</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Cardiovascular Science</gtr:department><gtr:description>LiverMultiscan with MRI - replacing liver biopsy</gtr:description><gtr:id>5B8E502B-D4B5-43AC-92D5-E9F05808CBB9</gtr:id><gtr:impact>TSB award to support this development</gtr:impact><gtr:outcomeId>cCKouGvgbAz-2</gtr:outcomeId><gtr:partnerContribution>Development and testing of image analysis in liver diease</gtr:partnerContribution><gtr:piContribution>One of two UK liver Centres (Edinburgh the second) involved this this project to validate 
 1. Production of LiverMultiscan software: led by Perspectum an Oxford spin-out company, but requiring clinician and imaging input to devlope LiverMultiscan prototype technology into a product that can be readily used in real world
clinical settings;
2. Quantification of liver fibrosis using liver biopsy histology as reference standard: we with Edinburgh host large academic liver programmes, and working together, with shared transnational aspirations, we will conduct independent evaluation of the new MRI technology as compared to current standard of care, as well as to other non-invasive approaches (blood biomarkers, fibroscan), in patients with liver disease;
3. The LiverMultiscan in the context of inhomogeneous liver disease: as part of a process of generality to all liver disease, a defined pilot study of MRI scanning in patients with primary sclerosing cholangitis will be performed, the
goal being to demonstrate the utility of imaging in a disease that is hetereogeneous, presently lacking therapy as well as
non-invasive surrogates of disease progression for use in both clinical trials and clinical practice.
4. The LiverMultiscan against histology in ex planted liver: finally as part of the important long term validation
process, Birmingham will use its unique access to fresh liver tissue to directly validate MRI findings with whole liver explant histologic findings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Perspectum Diagnosis</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>LiverMultiscan with MRI - replacing liver biopsy</gtr:description><gtr:id>B5923D4B-39F3-4616-B639-9AFDA686C0BE</gtr:id><gtr:impact>TSB award to support this development</gtr:impact><gtr:outcomeId>cCKouGvgbAz-1</gtr:outcomeId><gtr:partnerContribution>Development and testing of image analysis in liver diease</gtr:partnerContribution><gtr:piContribution>One of two UK liver Centres (Edinburgh the second) involved this this project to validate 
 1. Production of LiverMultiscan software: led by Perspectum an Oxford spin-out company, but requiring clinician and imaging input to devlope LiverMultiscan prototype technology into a product that can be readily used in real world
clinical settings;
2. Quantification of liver fibrosis using liver biopsy histology as reference standard: we with Edinburgh host large academic liver programmes, and working together, with shared transnational aspirations, we will conduct independent evaluation of the new MRI technology as compared to current standard of care, as well as to other non-invasive approaches (blood biomarkers, fibroscan), in patients with liver disease;
3. The LiverMultiscan in the context of inhomogeneous liver disease: as part of a process of generality to all liver disease, a defined pilot study of MRI scanning in patients with primary sclerosing cholangitis will be performed, the
goal being to demonstrate the utility of imaging in a disease that is hetereogeneous, presently lacking therapy as well as
non-invasive surrogates of disease progression for use in both clinical trials and clinical practice.
4. The LiverMultiscan against histology in ex planted liver: finally as part of the important long term validation
process, Birmingham will use its unique access to fresh liver tissue to directly validate MRI findings with whole liver explant histologic findings.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biotie Therapies</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>VAP-1</gtr:description><gtr:id>F4DBBAEE-67FF-49A9-810E-AEFFB02519FD</gtr:id><gtr:impact>2 patents
several publication
recent EME award</gtr:impact><gtr:outcomeId>cX773CuyEr9-1</gtr:outcomeId><gtr:partnerContribution>Biotie therapeutic antibodies
University of Turku reagents and intellectual collaboration</gtr:partnerContribution><gtr:piContribution>On going collaboration on a liver endothelial receptor VAP-1. We have defined this as a biomarker and theraeutic traget in liver disease resulting in a recent award of an EME grant fund a proof of concept clinical trial</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biotie Therapies</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>Levitates EU Marie Curie TOK programme</gtr:description><gtr:id>2DEA7D75-4883-416E-ACE0-3953ACC7B7DC</gtr:id><gtr:impact>Two patents on VAP-1 as a biomarker and as a therapeutic target in liver disease. Publications in preparation Pubmed ID 17911464</gtr:impact><gtr:outcomeId>60DB17C95A0-2</gtr:outcomeId><gtr:partnerContribution>Research collaboration and transfer of knowledge and reagentsResearch collaboration and transfer of reagents and technologies</gtr:partnerContribution><gtr:piContribution>This is an EU funded two centre collaboration with Biotie therapies in Finland to develop VAP-1 as a theraeutic target in liver disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Ludwigs University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Research fellowship</gtr:description><gtr:id>42446FF9-2D40-439D-BD56-C87051E6B307</gtr:id><gtr:impact>Conference presentation
Publications in preparation</gtr:impact><gtr:outcomeId>58c7a729cdefe9.78582530-1</gtr:outcomeId><gtr:partnerContribution>Funded research fellow</gtr:partnerContribution><gtr:piContribution>EU funded research fellowship for Nico Buettner to visit our laboratory for 2 years</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biotie Therapies</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>Levitates EU Marie Curie TOK programme</gtr:description><gtr:id>D4198BAB-D821-419D-8832-92B66B94830C</gtr:id><gtr:impact>Two patents on VAP-1 as a biomarker and as a therapeutic target in liver disease. Publications in preparation Pubmed ID 17911464</gtr:impact><gtr:outcomeId>60DB17C95A0-1</gtr:outcomeId><gtr:partnerContribution>Research collaboration and transfer of knowledge and reagentsResearch collaboration and transfer of reagents and technologies</gtr:partnerContribution><gtr:piContribution>This is an EU funded two centre collaboration with Biotie therapies in Finland to develop VAP-1 as a theraeutic target in liver disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Turku</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>MediCity Research Laboratory</gtr:department><gtr:description>VAP-1</gtr:description><gtr:id>F03A880D-A266-4BAF-8717-C30D653661EB</gtr:id><gtr:impact>2 patents
several publication
recent EME award</gtr:impact><gtr:outcomeId>cX773CuyEr9-2</gtr:outcomeId><gtr:partnerContribution>Biotie therapeutic antibodies
University of Turku reagents and intellectual collaboration</gtr:partnerContribution><gtr:piContribution>On going collaboration on a liver endothelial receptor VAP-1. We have defined this as a biomarker and theraeutic traget in liver disease resulting in a recent award of an EME grant fund a proof of concept clinical trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>World hepatitis day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>63CD22A0-DD07-403E-9C95-CBBB73BA8155</gtr:id><gtr:impact>-Hosted public meeting for World hepatitis day attended by patient groups, politicians, press. Featured on Kerrang Radio &amp;amp; Naked scientist website http://www.thenakedscientists.com/HTML/podcasts/specials/show/2009.06.10/

Increased profile</gtr:impact><gtr:outcomeId>0C8CE80D0FF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trustee PSC Support</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9D082535-C6E7-4B90-A23A-197F8687A41B</gtr:id><gtr:impact>Trustee of patients support charity responsible for overseeing charity and organising meeting to share research advances</gtr:impact><gtr:outcomeId>58c7a292ec3cb5.25861263</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.pscsupport.org.uk/?gclid=CjwKEAjwqZ7GBRC1srKSv9TV_iwSJADKTjaDl5WWgqCsixq9oG84SRlUY8FyF_2Um36QfNYcN2vUExoC8F7w_wcB</gtr:url><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PPI initiatve</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3DE21B64-3447-4D57-AB70-25EF753B3B12</gtr:id><gtr:impact>20 members of the public and patients attended a seminar/workshop on liver research in Birmingham

Panel agreed to review our research patient information sheets</gtr:impact><gtr:outcomeId>ZMPDyVKvSQr</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AASLDTV on Youtube</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B56060B7-B4C1-4F86-B836-3ADB0E4B566A</gtr:id><gtr:impact>The film that we made for AASLDTV is now on Youtube and links have been put onto our own and other websites including the PSC Support Group Website (URL below)

There has been a great deal of interest amongst our patient support groups and we have had positive feedback from the PSC Support Group. The Chair of PSC Support, commented that &amp;quot;This is welcome news for patients with diseases like Primary Sclerosing Cholangitis, which currently has no effective treatment. Knowing that the unit is at the cutting edge of medicine and focused on developing novel therapies for liver disease including PSC gives such hope to patients. The unit works closely with patients and patient groups and we can be confident that these outstanding clinicians will continue to make unique breakthroughs in research and medicine to help patients with liver disease.&amp;quot;</gtr:impact><gtr:outcomeId>PYZAcxE4iL6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.pscsupport.org.uk/news/exciting-era-translational-research</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Development of a PPI panel</gtr:description><gtr:form>A formal working group, expert panel or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>150E0B5F-3238-4046-9660-6808F9F1F0BC</gtr:id><gtr:impact>In 2009 we held an education day and recruited 20 PPI panel members who were interested in liver research. Our Liver PPI panel is now well established. Members attend meetings on liver disease and liver research twice a year. The panel contribute to the research process and collaborate with researchers on patient Information sheets, consent forms and lay summaries for academic and pharma studies and grant applications. Their comments have been pertinent and useful to the researchers- for example the panel asked for explanations of &amp;quot;minimal risk&amp;quot; and clarification of what samples would be taken in one study. They also provide positive feedback - e.g. a &amp;quot;scheduled procedure timetable&amp;quot; was of great value, &amp;quot;success of the study may not be of benefit to the patient but perhaps for others&amp;quot;. In another study they raised specific questions about a definition, whether the trial was worthwhile and if the recruitment target was achievable in a sensible time frame. The panel have developed into a well- informed resource who provide invaluable and sometimes challenging feedback which has a positive benefit for the BRU research programme We have proactive PPI members (2 patients and one lay) on the strategy board who bring very different and challenging perspectives to the BRU. They provide strategic advice on stakeholder related aspects of the research programme but they also offer tactical guidance on governance and finance

The impact of the panel has been significant in several areas. The panel are now well informed and are able to offer constructive advice on our research. One panel member is assisting with literature searches and reviews. Being engaged allows PPI members to share best practice about research and to champion the research being undertaken within the BRU to the wider community. Members regularly participate in open days and public engagement events along with researchers from the BRU. They also instigated and regularly contribute to &amp;quot;Liver Focus&amp;quot; a biannual news letter on our research in liver disease. We continue to evaluate the effect of the panel through an annual survey to panel members (also part of a UHB initiative). We are developing a robust evaluation tool through the BRU that will allow them to assess the PPI panel's impact on how they deliver their research portfolio and to ensure that their involvement is positive.

Other benefits to the BRU include better designed clinical studies and trials; more accessible patient information, resulting in improvements in informed consent; education of the public about liver disease and the importance and potential of research and clinical trials</gtr:impact><gtr:outcomeId>LYUsSRhFUv8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.birmingham.ac.uk/research/activity/mds/centres/liver/involvement/index.aspx</gtr:url><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schools</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>177EC202-1E6B-4FAB-9CB4-1DC226AC3546</gtr:id><gtr:impact>-Students from local schools come to the department to learn about research and to carry out short projects

Goldcrest award and Nuffield Bursary award</gtr:impact><gtr:outcomeId>0E89892AB14</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Guardian</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>57EAF4A4-1641-426D-970D-5F0C471ABC6E</gtr:id><gtr:impact>-Article in the Guardian on liver disease and transplantation www.guardian.co.uk/society/2008/nov/28/organ-donation-health-policy-transplant

Incraesed public profile</gtr:impact><gtr:outcomeId>45483200ABD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PSC</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F89A4471-83FA-479B-ACB3-C67D78ED0759</gtr:id><gtr:impact>Hosted meeting of the PSC patient group to discuss our research
Took on role as Trustee of the Charity in 2013

Asked to host the meeting on an annual basis
Helped develop a research funding programme for the charity
Helped write guieldlines and provide clinical advice</gtr:impact><gtr:outcomeId>33AB7E04BFD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.pscsupport.org.uk/?gclid=Cj0KEQiAp4yjBRCE_enjmpug944BEiQATCpLvU1wXwOybMo7BSFeWs_AEICLJAiyNnTvcfLZfY4HACIaApBA8P8HAQ</gtr:url><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public engagement</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>61F97171-740D-4706-BACF-2634D7E6D2C0</gtr:id><gtr:impact>PSC Trust meeting London

Discussion of the potential for stem cell therapy in liver disease. A funding initiative to support genomics in liver disease.</gtr:impact><gtr:outcomeId>2844A885C99</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Research Training Fellowship</gtr:department><gtr:description>Wellcome Trust Clinical Fellowship</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>7F9B7523-8AAE-4D9B-800C-3B9D5422661A</gtr:id><gtr:outcomeId>545254ad5617d0.54198521</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EME Project:12/165/31 - Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC).</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>EME  Project:12/165/31 - Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC).</gtr:fundingRef><gtr:id>0D576321-4F70-4739-AC60-D23F6FD64912</gtr:id><gtr:outcomeId>545253bb805878.37331956</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>330065</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project grant (The role of vascular adhesion protein-1 in leucocyte transmigration across liver endothelium)</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E530734C-283C-4D79-9573-5A997397D636</gtr:id><gtr:outcomeId>C75FEE733A00</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>450000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie TOK</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>F5E378A0-4088-4AC1-A7DC-DDE95674F2AE</gtr:id><gtr:outcomeId>8378C7EC45B0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Birmingham Liver Biomedical Research Unit</gtr:department><gtr:description>NIHR BRU in Cell and Immunotherapy for LIver disease</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B66B8901-7F7F-46FB-B29E-F1DEECDECEA5</gtr:id><gtr:outcomeId>42EC3D4A5A40</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR BRU</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>70D7E36F-BBF8-44D2-BE81-B8435133021F</gtr:id><gtr:outcomeId>5452573cc54157.60860409</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>H2020_COLLAB_HEP-CAR</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>E00EB5B7-6ACE-4C60-AC74-D4AFFA459356</gtr:id><gtr:outcomeId>56dd75ccddb722.97894132</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enterprising Birmingham Fund (Felicity de Cogan)</gtr:description><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>8C8CEEC4-D6FD-4934-B359-A3E66B420D69</gtr:id><gtr:outcomeId>58b8337607e9f8.99306959</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Research Training Fellowship</gtr:department><gtr:description>Clinical training fellowship</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A8B1CC16-2F04-4590-AE1C-CF90DD319FAE</gtr:id><gtr:outcomeId>0EC16ED59540</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0700301</gtr:fundingRef><gtr:id>BC563BAC-CFC9-4AC3-886F-C631C0D2ACED</gtr:id><gtr:outcomeId>C9CBE0609940</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of VAP-1 as a theraeutic target for liver disease</gtr:description><gtr:grantRef>G0300101</gtr:grantRef><gtr:id>708D595F-747E-4A6F-B6F0-8C8166FAE212</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>eyp222aiMAF</gtr:outcomeId><gtr:patentId>TW201134484</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Use of VAP-1 inhibitors to treat fibrotic diseases</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>We reported the use of sVAP-1 as a biomarker for liver fibrosis

The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.</gtr:description><gtr:grantRef>G0300101</gtr:grantRef><gtr:id>67BF8283-6B02-4CB2-B1F5-5E61B199B0C6</gtr:id><gtr:impact>Second patent pending</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>D1116A07D2D</gtr:outcomeId><gtr:patentId>WO2011029996</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>sVAP-1 as a biomarker in liver fibrosis</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We made mutant forms of teh protein expressed in cell lines</gtr:description><gtr:id>5F7725CC-C0E1-46BE-AE22-7FD9C43CB98A</gtr:id><gtr:impact>Have promoted our progress</gtr:impact><gtr:outcomeId>0AC23C0DFE1</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Transfectants</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CD980771-C0C3-4A65-A0B0-5DE0AB5DC001</gtr:id><gtr:title>Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_14820_20_24259385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4379367-802E-46F5-9226-1C41AADF7F93</gtr:id><gtr:title>Hepatic consequences of vascular adhesion protein-1 expression.</gtr:title><gtr:parentPublicationTitle>Journal of neural transmission (Vienna, Austria : 1996)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e6606ad68423212b7bb8721b236d8d3"><gtr:id>1e6606ad68423212b7bb8721b236d8d3</gtr:id><gtr:otherNames>Weston CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-9564</gtr:issn><gtr:outcomeId>544fcab8b4d778.87216890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EB76060-5F38-40CC-9269-6868AD87FE8E</gtr:id><gtr:title>Vascular adhesion protein-1 as a potential therapeutic target in liver disease.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1206da15539ea3f88193f0cde366d1ac"><gtr:id>1206da15539ea3f88193f0cde366d1ac</gtr:id><gtr:otherNames>Lalor PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>544fcab7b519b9.05945487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9412E9F4-8A50-426E-9BD1-E59F1BA22B93</gtr:id><gtr:title>Lymphocyte recruitment to the liver: molecular insights into the pathogenesis of liver injury and hepatitis.</gtr:title><gtr:parentPublicationTitle>Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd20de4d5c14af8cc708d7b67c01f07e"><gtr:id>bd20de4d5c14af8cc708d7b67c01f07e</gtr:id><gtr:otherNames>Shetty S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-483X</gtr:issn><gtr:outcomeId>F0B2CCBF6C2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDC2CAC1-D9AD-4F2E-A4A6-5988E743F0A4</gtr:id><gtr:title>Regulatory T cells and autoimmune hepatitis: defective cells or a hostile environment?</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/736816f8f545c53af3577861e58e44cd"><gtr:id>736816f8f545c53af3577861e58e44cd</gtr:id><gtr:otherNames>Oo YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_14820_20_22522382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41DCA76F-D7DF-4A93-ABAF-F0ADA8BDD3E0</gtr:id><gtr:title>Mucosal immunity in liver autoimmunity: a comprehensive review.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15e68c617b011357137d3bb9f8bef859"><gtr:id>15e68c617b011357137d3bb9f8bef859</gtr:id><gtr:otherNames>Trivedi PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>pm_14820_20_23891169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6BFFDD9-76B0-48DF-80D0-FEE06C1EE01E</gtr:id><gtr:title>Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_14820_20_23775568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E5A15C5-0C45-4D31-B4FF-7C7725F3B877</gtr:id><gtr:title>Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2ec17573a7d601b84c252ca07eecde4"><gtr:id>e2ec17573a7d601b84c252ca07eecde4</gtr:id><gtr:otherNames>Liaskou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_14820_20_22911542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4949E396-3EB7-4EB0-9E14-96BF86F79957</gtr:id><gtr:title>Hepatic sinusoidal endothelium avidly binds platelets in an integrin-dependent manner, leading to platelet and endothelial activation and leukocyte recruitment.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1206da15539ea3f88193f0cde366d1ac"><gtr:id>1206da15539ea3f88193f0cde366d1ac</gtr:id><gtr:otherNames>Lalor PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>pm_14820_20_23257923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEA5542D-900A-4DC4-9173-0B2A5BE0D10A</gtr:id><gtr:title>CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c52b1deea6d33589dd0d7adec320dbc6"><gtr:id>c52b1deea6d33589dd0d7adec320dbc6</gtr:id><gtr:otherNames>Miles A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>79ED01722AA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6673D686-9777-4BC5-976D-EC1874EC1C18</gtr:id><gtr:title>Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e6606ad68423212b7bb8721b236d8d3"><gtr:id>1e6606ad68423212b7bb8721b236d8d3</gtr:id><gtr:otherNames>Weston CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>56dd6a578b6dc6.39084656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C72E0A56-217D-42F4-A6F6-34350791EA95</gtr:id><gtr:title>Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd20de4d5c14af8cc708d7b67c01f07e"><gtr:id>bd20de4d5c14af8cc708d7b67c01f07e</gtr:id><gtr:otherNames>Shetty S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>544fcab8851b22.75037500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74458ECF-94CE-49F5-8E97-51BFCC1B1F61</gtr:id><gtr:title>CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e8c9326e8cd06b12184818865d7651f"><gtr:id>4e8c9326e8cd06b12184818865d7651f</gtr:id><gtr:otherNames>Aspinall AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>544fcab7e44d19.57306126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B5AB64C-02D5-4844-9CCA-ACCC04E22791</gtr:id><gtr:title>CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/736816f8f545c53af3577861e58e44cd"><gtr:id>736816f8f545c53af3577861e58e44cd</gtr:id><gtr:otherNames>Oo YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_14820_20_22796894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25CA4BE2-5945-4028-AC2D-CF3483AA0DD2</gtr:id><gtr:title>An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d3f56c0819d7020f055b81152123f37"><gtr:id>6d3f56c0819d7020f055b81152123f37</gtr:id><gtr:otherNames>Karim S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>pm_14820_20_23300006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BEFE778-2750-46EA-9177-07405FEC343C</gtr:id><gtr:title>Haematopoietic stem cell recruitment to injured murine liver sinusoids depends on (alpha)4(beta)1 integrin/VCAM-1 interactions.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82eaf2702ece671687f68c6a458560fb"><gtr:id>82eaf2702ece671687f68c6a458560fb</gtr:id><gtr:otherNames>Kavanagh DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>96F67D746AE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDAF37CB-2F4C-460F-9F4C-DE6E1319CA62</gtr:id><gtr:title>Chemokines in the immunopathogenesis of hepatitis C infection.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/890266f4d18e3b6fd4ad1b7fb34ba25c"><gtr:id>890266f4d18e3b6fd4ad1b7fb34ba25c</gtr:id><gtr:otherNames>Heydtmann M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>A5575006506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E152F8F4-049B-43BE-BE5D-FD0100E974A7</gtr:id><gtr:title>Primary sclerosing cholangitis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb0cc0109e179d19fdeb7c8dc774a9c6"><gtr:id>bb0cc0109e179d19fdeb7c8dc774a9c6</gtr:id><gtr:otherNames>Hirschfield GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_14820_20_23810223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B11A32A-D6A8-48CB-BE40-AEE9F67680C1</gtr:id><gtr:title>The regulation of T-cell recruitment to the human liver during acute liver failure.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fb0670214d5bc63d29e42ea5eab49fb"><gtr:id>6fb0670214d5bc63d29e42ea5eab49fb</gtr:id><gtr:otherNames>Tuncer C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>544fcaaf7320c9.80190235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB245522-8932-4902-9601-3003351848F7</gtr:id><gtr:title>Cellular localization and trafficking of vascular adhesion protein-1 as revealed by an N-terminal GFP fusion protein.</gtr:title><gtr:parentPublicationTitle>Journal of neural transmission (Vienna, Austria : 1996)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e6606ad68423212b7bb8721b236d8d3"><gtr:id>1e6606ad68423212b7bb8721b236d8d3</gtr:id><gtr:otherNames>Weston CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-9564</gtr:issn><gtr:outcomeId>544fcab27c4fb2.56079510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FDAAAD6-30AA-4969-B434-884C7F77AF0E</gtr:id><gtr:title>Evaluation of serum lysyl oxidase as a blood test for colorectal cancer.</gtr:title><gtr:parentPublicationTitle>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34f318794f9294e886d3e13f3830ccfa"><gtr:id>34f318794f9294e886d3e13f3830ccfa</gtr:id><gtr:otherNames>Ward ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0748-7983</gtr:issn><gtr:outcomeId>pm_14820_20_24246612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9BE8212-FC3F-411F-97B8-3CE50ACF584B</gtr:id><gtr:title>Dysregulated hepatic expression of glucose transporters in chronic disease: contribution of semicarbazide-sensitive amine oxidase to hepatic glucose uptake.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d3f56c0819d7020f055b81152123f37"><gtr:id>6d3f56c0819d7020f055b81152123f37</gtr:id><gtr:otherNames>Karim S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>544fcab596e494.74115614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>686D0F54-0F48-42F7-8970-9932115C8E7E</gtr:id><gtr:title>Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1206da15539ea3f88193f0cde366d1ac"><gtr:id>1206da15539ea3f88193f0cde366d1ac</gtr:id><gtr:otherNames>Lalor PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>3625C7C9ACE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47E93ADC-41FC-48E8-88CA-8F163C1C06CA</gtr:id><gtr:title>Activation of vascular adhesion protein-1 on liver endothelium results in an NF-kappaB-dependent increase in lymphocyte adhesion.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1206da15539ea3f88193f0cde366d1ac"><gtr:id>1206da15539ea3f88193f0cde366d1ac</gtr:id><gtr:otherNames>Lalor PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5A7B223C941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00021BD3-72EE-4D1C-82A6-78B52B3E2E59</gtr:id><gtr:title>A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e367a92edf320c5b0b28e09e11f0c97"><gtr:id>2e367a92edf320c5b0b28e09e11f0c97</gtr:id><gtr:otherNames>Palmer DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>FEC9A8E997C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5EC2186-BB20-4C90-80D1-D1232238C19C</gtr:id><gtr:title>Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2ec17573a7d601b84c252ca07eecde4"><gtr:id>e2ec17573a7d601b84c252ca07eecde4</gtr:id><gtr:otherNames>Liaskou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>544fcab8585d55.20967216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0D3E51D-E2E4-43F3-891C-7CBE4BD9EBA2</gtr:id><gtr:title>Adhesion of human haematopoietic (CD34+) stem cells to human liver compartments is integrin and CD44 dependent and modulated by CXCR3 and CXCR4.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93b3d395eebb982c9c567e90cb953378"><gtr:id>93b3d395eebb982c9c567e90cb953378</gtr:id><gtr:otherNames>Crosby HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>895244A8E4E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>827EAD05-C479-42C8-8C2D-0012CC544A5A</gtr:id><gtr:title>Mechanisms of immune-mediated liver injury.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/856c31f0b7d46b833b854dca3afb28a6"><gtr:id>856c31f0b7d46b833b854dca3afb28a6</gtr:id><gtr:otherNames>Adams DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>AiwPJUnkWa3</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300101</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>